自體顯性多囊腎疾病(autosomal dominant polycystic kidney disease; ADPKD)是最常見且具威脅生命的遺傳疾病之一，大多數病人主要是PKD1 的基因發生突變。運用傳統式或條件式的基因剔除法，將小鼠直系同源基因Pkd1剔除，進而重現與人類疾病表現型特徵相似的模式鼠一直尚未成功地建立。我們先前建立一個新穎的Pkd1 hypomorphic allele，其Pkd1基因之表達顯著地被降低而非完全阻斷。這些Pkd1同型合子(homozygote)突變的老鼠會迅速發展出多囊腎疾病，此支持自體顯性多囊腎是haploinsufficiency之假說。我們進一步想探討Pkd1基因之haploinsufficiency效應，透過co-cistron表達對Pkd1轉錄專一性的兩種微型核糖核酸，以建構Pkd1基因表現減量的轉殖鼠。此兩種轉基因株系的老鼠其Pkd1基因表現約減量60-70%，並且與人類自體顯性多囊腎疾病的病程相類似。這些結果進一步支持haploinsufficiency的假說，並且推測多囊腎疾病的發生與進展是與Pkd1基因表現量息息相關。因此，此兩種基因轉殖鼠可以作為研究自體顯性多囊腎疾病的理想模式鼠。
嗜中性白血球膠原蛋白質酶相關疏水性蛋白質（Neutrophil gelatinase-associated lipocalin; Ngal）是急性和慢性腎損傷(其中也包括多囊腎疾病）的生物標誌物。然而，Ngal基因對多囊腎疾病進展之影響尚未被探討。為了闡明Ngal在PKD中的作用，我們利用已建立的多囊腎疾病小鼠模式（Pkd1L3 / L3小鼠）產生了具有不同表達程度的Ngal的三種小鼠：Pkd1L3 / L3（具有內源性Ngal基因），Pkd1L3 / L3; NgalTg / Tg（具有內源性和過表達外源性腎臟專一性的Ngal基因）和Pkd1L3 / L3; Ngal - / - 小鼠（具有Ngal基因缺失）。內源性Ngal基因的剔除對Pkd1L3 / L3小鼠的表現型，囊泡進展或存活率沒有影響。然而，與具有內源性Ngal基因或Ngal基因剔除的小鼠相比，Pkd1L3 / L3; NgalTg / Tg小鼠具有顯著性更長的壽命，更小的（並非數目較少的）腎囊泡和更輕微的間質纖維化。西方墨點分析法顯示Pkd1L3 / L3; NgalTg / Tg小鼠與其他兩組PKD小鼠相比，其Ngal表現和活化的細胞凋亡蛋白質-3 (active caspase 3)有顯著性地增加，並且其α-平滑肌肌動蛋白(α-smooth muscle actin)、缺氧誘導因子-1α (hypoxia-inducible factor 1-α)、凋亡蛋白質酶原-3 (pro-caspase 3)、增殖細胞核抗原 (proliferating cell nuclear antigen)、Akt、哺乳動物雷帕霉素靶蛋白質 (mammalian target of rapamycin)和S6激酶有顯著性地減少。總之，過度表達外源性腎臟專一性的Ngal可以減少囊泡進展並延長PKD小鼠的壽命，其分子病理機轉是透過減少腎臟囊泡之生長，減緩腎間質性之纖維化，減少囊泡上皮細胞之增殖並且增加囊泡上皮細胞之細胞凋亡有關。

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common life-threatening inherited diseases, and the PKD1 gene is responsible for most cases of this disease. Establishing a mouse model to recapitulate the phenotypic characteristics of ADPKD, which have used conventional or conditional knockout of the mouse orthologue Pkd1, have been unsuccessful. We previously established a novel Pkd1 hypomorphic allele, in which Pkd1 expression was significantly reduced but not totally blocked. These Pkd1 homozygous mutant mice rapidly developed renal cystic disease, supporting the hypothesis that ‘haploinsufficiency’ explains development of the ADPKD phenotype. We further explored the Pkd1 haploinsufficiency effect by generating Pkd1 knockdown transgenic mice with co-cistronic expressing of two miRNA hairpins specific to Pkd1 transcript. Two transgenic lines which had about 60 to 70% reduction of Pkd1 expression developed renal cystic disease at a rate similar to that of human ADPKD. These results further support the haploinsufficiency hypothesis, and suggest that the onset and progression of the renal cystic diseases are closely associated with the level of Pkd1 expression. These two mutant lines of mice could be ideal models for the study of ADPKD.

Neutrophil gelatinase-associated lipocalin (Ngal) is a biomarker for acute and chronic renal injuries, including polycystic kidney disease (PKD); however, the effect of Ngal on PKD progression remains unexplored. To clarify the role of Ngal in PKD, we generated three kinds of mice with different expression levels of Ngal based on an established PKD model (Pkd1L3/L3 mice): Pkd1L3/L3 (with endogenous Ngal), Pkd1L3/L3; NgalTg/Tg (with endogenous and overexpression of exogenous kidney-specific Ngal) and Pkd1L3/L3; Ngal-/- mice (with Ngal deficiency). Knockout of endogenous Ngal had no effect on phenotypes, cystic progression or survival of Pkd1L3/L3 mice. However, the Pkd1L3/L3; NgalTg/Tg mice had a significantly longer lifespan, smaller (but not fewer) renal cysts and less interstitial fibrosis than the mice with endogenous Ngal or without Ngal. Western-blot analyses showed significant increases in Ngal and active caspase-3, and decreases in α-smooth muscle actin, hypoxia-inducible factor 1-α, pro-caspase 3, proliferating cell nuclear antigen, Akt, mammalian target of rapamycin, and S6 Kinase in the Pkd1L3/L3; NgalTg/Tg mice as compared with the other two groups of PKD mice. In conclusion, overexpression of exogenous kidney-specific Ngal could reduce cystic progression and prolong the lifespan in PKD mice, and the molecular pathomechanisms were associated with reductions in cystic growth, interstitial fibrosis and proliferation, and augmentation of apoptosis.

1. Harris PC, Bae KT, Rossetti S, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. Journal of the American Society of Nephrology : JASN 2006; 17: 3013-3019.

2. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2003; 23 Suppl 1: 14-22.

3. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell 1994; 78: 725.

4. Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272: 1339-1342.

5. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301.

6. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nature reviews Nephrology 2011; 7: 556-566.

7. Brasier JL, Henske EP. Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. The Journal of clinical investigation 1997; 99: 194-199.

8. Lu W, Peissel B, Babakhanlou H, et al. Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nature genetics 1997; 17: 179-181.

9. Lu W, Fan X, Basora N, et al. Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nature genetics 1999; 21: 160-161.

10. Wu G, Markowitz GS, Li L, et al. Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nature genetics 2000; 24: 75-78.

11. Ong AC, Harris PC, Davies DR, et al. Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue. Kidney international 1999; 56: 1324-1333.

12. Piontek K, Menezes LF, Garcia-Gonzalez MA, et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nature medicine 2007; 13: 1490-1495.

13. Takakura A, Contrino L, Zhou X, et al. Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. Human molecular genetics 2009; 18: 2523-2531.

14. Doerr N, Wang Y, Kipp KR, et al. Regulation of Polycystin-1 Function by Calmodulin Binding. PloS one 2016; 11: e0161525.

15. Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nature genetics 2003; 33: 129-137.

16. Qian F, Germino FJ, Cai YQ, et al. PKD1 interacts with PKD2 through a probable coiled-coil domain. Nature genetics 1997; 16: 179-183.

17. Hama T, Park F. Heterotrimeric G protein signaling in polycystic kidney disease. Physiological genomics 2016; 48: 429-445.

18. Hopp K, Ward CJ, Hommerding CJ, et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. The Journal of clinical investigation 2012; 122: 4257-4273.

19. Fedeles SV, Gallagher AR, Somlo S. Polycystin-1: a master regulator of intersecting cystic pathways. Trends in molecular medicine 2014; 20: 251-260.

20. Magenheimer BS, St John PL, Isom KS, et al. Early embryonic renal tubules of wild-type and polycystic kidney disease kidneys respond to cAMP stimulation with cystic fibrosis transmembrane conductance regulator/Na(+),K(+),2Cl(-) Co-transporter-dependent cystic dilation. Journal of the American Society of Nephrology : JASN 2006; 17: 3424-3437.

21. Watnick T, Germino G. From cilia to cyst. Nature genetics 2003; 34: 355-356.

22. Weimbs T. Third-hit signaling in renal cyst formation. Journal of the American Society of Nephrology : JASN 2011; 22: 793-795.

23. Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. The Journal of clinical investigation 2014; 124: 2315-2324.

24. Ong AC, Harris PC. A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney international 2015; 88: 699-710.

25. Wang E, Hsieh-Li HM, Chiou YY, et al. Progressive renal distortion by multiple cysts in transgenic mice expressing artificial microRNAs against Pkd1. The Journal of pathology 2010; 222: 238-248.

26. Starremans PG, Li X, Finnerty PE, et al. A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1. Kidney international 2008; 73: 1394-1405.

27. Takakura A, Contrino L, Beck AW, et al. Pkd1 inactivation induced in adulthood produces focal cystic disease. Journal of the American Society of Nephrology : JASN 2008; 19: 2351-2363.

28. Jiang ST, Chiou YY, Wang E, et al. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1. The American journal of pathology 2006; 168: 205-220.

29. Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, et al. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Human molecular genetics 2004; 13: 3069-3077.

30. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.

31. Tijsterman M, Plasterk RH. Dicers at RISC; the mechanism of RNAi. Cell 2004; 117: 1-3.

32. Yang J, Goetz D, Li JY, et al. An iron delivery pathway mediated by a lipocalin. Molecular cell 2002; 10: 1045-1056.

33. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432: 917-921.

34. Berger T, Togawa A, Duncan GS, et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 1834-1839.

35. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. Journal of the American Society of Nephrology : JASN 2003; 14: 2534-2543.

36. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.

37. Urbschat A, Gauer S, Paulus P, et al. Serum and urinary NGAL but not KIM-1 raises in human postrenal AKI. European journal of clinical investigation 2014; 44: 652-659.

38. Di Grande A, Giuffrida C, Carpinteri G, et al. Neutrophil gelatinase-associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury in the emergency department. European review for medical and pharmacological sciences 2009; 13: 197-200.

39. Devarajan P. NGAL for the detection of acute kidney injury in the emergency room. Biomarkers in medicine 2014; 8: 217-219.

40. Nickolas TL, Forster CS, Sise ME, et al. NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney international 2012; 82: 718-722.

41. Natoli TA, Smith LA, Rogers KA, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nature medicine 2010; 16: 788-792.

42. Parikh CR, Dahl NK, Chapman AB, et al. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney international 2012; 81: 784-790.

43. Meijer E, Boertien WE, Nauta FL, et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation 2010; 56: 883-895.

44. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. The Journal of clinical investigation 2005; 115: 610-621.

45. Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. Journal of the American Society of Nephrology : JASN 2004; 15: 3073-3082.

46. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney international 2007; 71: 967-970.

47. Tong Z, Wu X, Ovcharenko D, et al. Neutrophil gelatinase-associated lipocalin as a survival factor. The Biochemical journal 2005; 391: 441-448.

48. Wei F, Karihaloo A, Yu Z, et al. Neutrophil gelatinase-associated lipocalin suppresses cyst growth by Pkd1 null cells in vitro and in vivo. Kidney international 2008; 74: 1310-1318.

49. Langelueddecke C, Roussa E, Fenton RA, et al. Lipocalin-2 (24p3/neutrophil gelatinase-associated lipocalin (NGAL)) receptor is expressed in distal nephron and mediates protein endocytosis. The Journal of biological chemistry 2012; 287: 159-169.

50. Devireddy LR, Gazin C, Zhu X, et al. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005; 123: 1293-1305.

51. Schmidt-Ott KM, Mori K, Li JY, et al. Dual action of neutrophil gelatinase-associated lipocalin. Journal of the American Society of Nephrology : JASN 2007; 18: 407-413.

52. Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer therapy 2007; 5: 463-470.

53. Wilson PD. Polycystic kidney disease. The New England journal of medicine 2004; 350: 151-164.

54. Okada H, Ban S, Nagao S, et al. Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney international 2000; 58: 587-597.

55. Higgins DF, Kimura K, Iwano M, et al. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell cycle 2008; 7: 1128-1132.

56. Buchholz B, Schley G, Faria D, et al. Hypoxia-inducible factor-1alpha causes renal cyst expansion through calcium-activated chloride secretion. Journal of the American Society of Nephrology : JASN 2014; 25: 465-474.

57. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Journal of the American Society of Nephrology : JASN 2006; 17: 17-25.

58. Bernhardt WM, Wiesener MS, Weidemann A, et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. The American journal of pathology 2007; 170: 830-842.

59. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. Journal of the American Society of Nephrology : JASN 2009; 20: 2493-2502.

60. Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. Journal of the American Society of Nephrology : JASN 2005; 16: 46-51.

61. Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. The New England journal of medicine 2010; 363: 820-829.

62. Perico N, Antiga L, Caroli A, et al. Sirolimus therapy to halt the progression of ADPKD. Journal of the American Society of Nephrology : JASN 2010; 21: 1031-1040.

63. Chen G, Chen H, Wang C, et al. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PloS one 2012; 7: e33626.

64. Torres VE, Boletta A, Chapman A, et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clinical journal of the American Society of Nephrology : CJASN 2010; 5: 1312-1329.

65. Shillingford JM, Piontek KB, Germino GG, et al. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. Journal of the American Society of Nephrology : JASN 2010; 21: 489-497.

66. Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney international 2011; 79: 502-511.

67. Edelstein CL. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clinical journal of the American Society of Nephrology : CJASN 2008; 3: 1219-1226.

68. Wertz K, Herrmann BG. Kidney-specific cadherin (cdh16) is expressed in embryonic kidney, lung, and sex ducts. Mechanisms of development 1999; 84: 185-188.

69. Thomson RB, Aronson PS. Immunolocalization of Ksp-cadherin in the adult and developing rabbit kidney. The American journal of physiology 1999; 277: F146-156.

70. Whyte DA, Li C, Thomson RB, et al. Ksp-cadherin gene promoter. I. Characterization and renal epithelial cell-specific activity. The American journal of physiology 1999; 277: F587-598.

71. Shao X, Johnson JE, Richardson JA, et al. A minimal Ksp-cadherin promoter linked to a green fluorescent protein reporter gene exhibits tissue-specific expression in the developing kidney and genitourinary tract. Journal of the American Society of Nephrology : JASN 2002; 13: 1824-1836.

72. Jiang ST, Chiou YY, Wang E, et al. Essential role of nephrocystin in photoreceptor intraflagellar transport in mouse. Human molecular genetics 2009; 18: 1566-1577.

73. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic acids research 2005; 33: e179.

74. Nagao S, Kusaka M, Nishii K, et al. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease. Journal of the American Society of Nephrology : JASN 2005; 16: 2052-2062.

75. Qin S, Taglienti M, Cai L, et al. c-Met and NF-kappaB-dependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease. Journal of the American Society of Nephrology : JASN 2012; 23: 1309-1318.

76. Sweeney WE, Jr., von Vigier RO, Frost P, et al. Src inhibition ameliorates polycystic kidney disease. Journal of the American Society of Nephrology : JASN 2008; 19: 1331-1341.

77. Valenzuela DM, Murphy AJ, Frendewey D, et al. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nature biotechnology 2003; 21: 652-659.

78. Mady HH, Melhem MF. FHIT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: an immunohistochemical and image analysis study. Clinical & experimental metastasis 2002; 19: 351-358.

79. Lakso M, Pichel JG, Gorman JR, et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 5860-5865.

80. Sise C, Kusaka M, Wetzel LH, et al. Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney international 2000; 58: 2492-2501.

81. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clinical journal of the American Society of Nephrology : CJASN 2006; 1: 148-157.

82. Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clinical journal of the American Society of Nephrology : CJASN 2012; 7: 479-486.

83. Higashihara E, Nutahara K, Okegawa T, et al. Kidney volume and function in autosomal dominant polycystic kidney disease. Clinical and experimental nephrology 2014; 18: 157-165.

84. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes & development 2004; 18: 1926-1945.

85. Orellana SA, Sweeney WE, Neff CD, et al. Epidermal growth factor receptor expression is abnormal in murine polycystic kidney. Kidney international 1995; 47: 490-499.

86. Du J, Wilson PD. Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. The American journal of physiology 1995; 269: C487-495.

87. Sweeney WE, Chen Y, Nakanishi K, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney international 2000; 57: 33-40.

88. Torres VE, Sweeney WE, Jr., Wang X, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney international 2003; 64: 1573-1579.

89. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. The EMBO journal 2004; 23: 4051-4060.

90. Lantinga-van Leeuwen IS, Leonhard WN, van der Wal A, et al. Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice. Human molecular genetics 2007; 16: 3188-3196.

91. Wilson PD. Mouse models of polycystic kidney disease. Current topics in developmental biology 2008; 84: 311-350.

92. Tao Y, Kim J, Faubel S, et al. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 6954-6959.

93. Tao Y, Zafar I, Kim J, et al. Caspase-3 gene deletion prolongs survival in polycystic kidney disease. Journal of the American Society of Nephrology : JASN 2008; 19: 749-755.

94. Viau A, El Karoui K, Laouari D, et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. The Journal of clinical investigation 2010; 120: 4065-4076.

95. Tao S, Kakade VR, Woodgett JR, et al. Glycogen synthase kinase-3beta promotes cyst expansion in polycystic kidney disease. Kidney international 2015; 87: 1164-1175.

本全文未授權公開